SABCS 2024 | APOBEC3 mutational signatures and therapy resistance in breast cancer

Name: APOBEC3 mutational signatures and therapy resistance in breast cancer
Uploaded: 2024-12-13T00:00:00Z
Duration: 1 min 36 s

Avantika Gupta • 13 Dec 2024

SABCS 2024

Breast Cancer

Avantika Gupta, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of APOBEC3 mutational signatures as biomarkers for poor treatment outcomes in metastatic breast cancer. In preclinical models, APOBEC3 mutagenesis promotes resistance to endocrine and targeted therapies, including CDK4/6 and HER2 inhibitors. Genomic instability caused by APOBEC3 activity contributes to therapy-resistant mutations, such as RB1 loss. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.